SynthesisFrontiers in public health2023
Association between per- and polyfluoroalkyl substances and risk of hypertension: a systematic review and meta-analysis.
Synthesis in Frontiers in public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 16 citations in OpenAlex.
- Endocrine-Disrupting Chemicals and Hypertension: Mechanisms and Clinical Implications.Journal of cardiovascular development and disease · 2026Review
- PFAS exposure and hypertension in US adults: A multi-method, cross-sectional analysis of NHANES 2005 to 2014.Medicine · 2026Article
- Per- and polyfluoroalkyl substances: A novel risk factor for cardiovascular disease.Ecotoxicology and environmental safety · 2026Review
- Serum Levels of Per- and Polyfluoroalkyl Substances in Adults Aged 18 and Older in Relation to the Length of Residency in United States.Journal of immigrant and minority health · 2026Article
- Mediating role of proteomics in the association between per- and polyfluoroalkyl substance exposure and blood pressure in youth.Environmental pollution (Barking, Essex : 1987) · 2025Article
- Per- and polyfluoroalkyl substances, apolipoproteins and the risk of coronary heart disease in US men and women.Environmental health : a global access science source · 2024Article
- Fish consumption benefits and PFAS risks: Epidemiology and public health recommendations.Toxicology reports · 2024Review
- Development, validation, and clinical assessment of a liquid chromatography-tandem mass spectrometry serum assay for per- and polyfluoroalkyl substances (PFAS) recommended by the National Academies of Science, Engineering, and Medicine (NASEM).Analytical and bioanalytical chemistry · 2024Article
- Developmental PFOS exposure alters lung inflammation and barrier integrity in juvenile mice.Toxicological sciences : an official journal of the Society of Toxicology · 2024Article
- Exposure to Environmental Toxins: Potential Implications for Stroke Risk via the Gut- and Lung-Brain Axis.Cells · 2024Review
- Perfluoroalkyl/Polyfluoroalkyl Substances: Links to Cardiovascular Disease Risk.Circulation research · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Existing evidence indicates that exposure to per- and polyfluoroalkyl substances (PFASs) may increase the risk of hypertension, but the findings are inconsistent. Therefore, we aimed to explore the relationship between PFASs and hypertension through this systematic review and meta-analysis. Methods: We searched PubMed, Embase, and the Web of Science databases for articles published in English that examined the relationship between PFASs and hypertension before 13 August 2022. The random effects model was used to aggregate the evaluation using Stata 15.0 for Windows. We also conducted subgroup analyses by region and hypertension definition. In addition, a sensitivity analysis was carried out to determine the robustness of the findings. Results: The meta-analysis comprised 15 studies in total with 69,949 individuals. The risk of hypertension was substantially and positively correlated with exposure to perfluorooctane sulfonate (PFOS) (OR = 1.31, 95% CI: 1.14, 1.51), perfluorooctanoic acid (PFOA) (OR = 1.16, 95% CI: 1.07, 1.26), and perfluorohexane sulfonate (PFHxS) (OR = 1.04, 95% CI: 1.00, 1.09). However, perfluorononanoic acid (PFNA) exposure and hypertension were not significantly associated (OR = 1.08, 95% CI: 0.99, 1.17). Conclusion: We evaluated the link between PFASs exposure and hypertension and discovered that higher levels of PFOS, PFOA, and PFHxS were correlated with an increased risk of hypertension. However, further high-quality population-based and pathophysiological investigations are required to shed light on the possible mechanism and demonstrate causation because of the considerable variability. Systematic review registration: https://www.crd.york.ac.uk/prospero/ PROSPERO, registration number: CRD 42022358142.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.